Out of the three healthcare buy recommendations, (CSL, SHL and RMD), made in the blog post back on 13th of September, CSL has increased 10% and SHL 10%+, however, RMD has been slower to recover. With the recent price action in RMD, we’re now more confident that a basing pattern, (or reversal), is beginning to take shape. Therefore, today’s post acts as a reminder that a buy opportunity in RMD remains, with an upside target of $9.00+
Resmed (RMD.ASX)
You're not a member! Trial today
